Atlas Shrugged: Part I

EverQuote Announces Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 6, 2023

Third Quarter Variable Marketing Margin of $19.4 million, Representing 35% of Revenue

Key Points: 
  • Third Quarter Variable Marketing Margin of $19.4 million, Representing 35% of Revenue
    CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- EverQuote, Inc. (Nasdaq: EVER), a leading online insurance marketplace, today announced financial results for the quarter ended September 30, 2023.
  • “We remain focused on streamlining our cost structure, maintaining financial flexibility, restoring a pattern of consistent cash generation, and driving towards profitability.”
    Third Quarter 2023 Financial Highlights:
    (Unless otherwise noted, all comparisons are relative to the third quarter of 2022.
  • EverQuote exited the health insurance vertical at the end of the second quarter of 2023.
  • EverQuote will host a conference call and live webcast to discuss its third quarter 2023 financial results at 4:30 p.m. Eastern Time today, November 6, 2023.

Kopin Corporation Provides Restructuring Update

Retrieved on: 
Thursday, January 19, 2023

Kopin® Corporation (Nasdaq:KOPN), a leading provider of application-specific optical solutions for defense, enterprise, industrial, and consumer products, today provided an update on its restructuring activities.

Key Points: 
  • Kopin® Corporation (Nasdaq:KOPN), a leading provider of application-specific optical solutions for defense, enterprise, industrial, and consumer products, today provided an update on its restructuring activities.
  • “On January 5, 2023, we announced a restructuring, which included the partial spinout of our OLED development unit and a reduction in force,” said Michael Murray, Kopin’s Chief Executive Officer.
  • “This week, we informed our employees that to accelerate application understanding, drive efficiencies and increase focus, we have reorganized the Company.
  • Kopin Corporation is a leading developer and provider of innovative application-specific optical solutions for integration into defense, enterprise, industrial, and consumer products.

Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

Retrieved on: 
Monday, December 5, 2022

: Commercial Successes, Current & Upcoming Launches.” The Company will also participate in one-on-one meetings during the conference.

Key Points: 
  • : Commercial Successes, Current & Upcoming Launches.” The Company will also participate in one-on-one meetings during the conference.
  • Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is focused on identifying, acquiring, developing and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model.
  • The Journey Medical team is comprised of industry experts with extensive experience commercializing some of the most successful prescription dermatology brands.
  • As used below and throughout this press release, the words “we”, “us” and “our” may refer to Journey Medical.

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, November 14, 2022

WORCESTER, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2022.

Key Points: 
  • WORCESTER, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2022.
  • We anticipate announcing early results from the Mustang-sponsored Phase 1 trial in December 2022.
  • Research and development expenses were $15.5 million for the third quarter of 2022, compared to $14.7 million for the third quarter of 2021.
  • General and administrative expenses were $3.4 million for the third quarter of 2022, compared to $2.4 million for the third quarter of 2021.

Horizon Global Announces Appointment of John C. Kennedy as Interim President and Chief Executive Officer

Retrieved on: 
Monday, November 21, 2022

Horizon Global Corporation (NYSE: HZN) (the Company), announced today that the Companys Board of Directors (the Board) appointed John C. Kennedy as Interim President and Chief Executive Officer.

Key Points: 
  • Horizon Global Corporation (NYSE: HZN) (the Company), announced today that the Companys Board of Directors (the Board) appointed John C. Kennedy as Interim President and Chief Executive Officer.
  • This appointment follows the Boards acceptance of Terrence G. Gohls resignation from his executive positions and as a director.
  • We remain focused on our strategic alternatives process, with our clear objective being to enhance shareholder value, stated Kennedy.
  • Horizon provides its customers with outstanding products and services that reflect the Company's commitment to market leadership, innovation and operational excellence.

Horizon Global Announces Receipt of Continued Listing Standard Notice From the NYSE

Retrieved on: 
Friday, November 11, 2022

The Company will notify the NYSE of its intent to cure the stock price deficiency and return to compliance with the continued listing standard.

Key Points: 
  • The Company will notify the NYSE of its intent to cure the stock price deficiency and return to compliance with the continued listing standard.
  • Horizon Global intends to closely monitor its stock price during the cure period and will, if necessary, consider available alternatives to cure the stock price non-compliance.
  • The Company's common stock will continue to be listed and traded on the NYSE during the cure period, subject to the Company's compliance with other NYSE continued listing standards.
  • Horizon Global is home to some of the worlds most recognized brands in the towing and trailering industry, including: Draw-Tite, Reese, Westfalia, BULLDOG, Fulton and Tekonsha.

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023

Retrieved on: 
Thursday, November 10, 2022

Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the second quarter of its fiscal year 2023, which ended on September 30, 2022.

Key Points: 
  • Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the second quarter of its fiscal year 2023, which ended on September 30, 2022.
  • Appili expects this program may be eligible for a Priority Review Voucher (PRV) if approved by the United States Food and Drug Administration (FDA).
  • Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections.
  • Led by a proven management team, Appili is at the epicenter of the global fight against infection.

Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences

Retrieved on: 
Tuesday, October 4, 2022

SCOTTSDALE, Ariz., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Journey Medical) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will participate in two upcoming investor conferences.

Key Points: 
  • SCOTTSDALE, Ariz., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Journey Medical) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will participate in two upcoming investor conferences.
  • Journey Medical Corporation (Nasdaq: DERM) (Journey Medical) is focused on identifying, acquiring, developing and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model.
  • The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatologys most successful prescription brands.
  • As used below and throughout this press release, the words we, us and our may refer to Journey Medical.

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

Retrieved on: 
Thursday, September 8, 2022

WORCESTER, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City.

Key Points: 
  • WORCESTER, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City.
  • ET and will participate in one-on-one meetings during the conference.
  • A webcast of the companys presentation will be available on the News & Events page of the Investor Relations section of Mustangs website, www.mustangbio.com , for approximately 30 days after the meeting.
  • Cantor Cell & Gene Therapy Conference: The company will participate in a panel presentation on Thursday, September 15, 2022, at 10:40 a.m.